Stock DNTH DIANTHUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-07-04 pm EDT 		5-day change 1st Jan Change
25.22 USD -4.65% Intraday chart for Dianthus Therapeutics, Inc. -12.64% +142.50%
Jul. 01 Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell Small Cap Comp Value Index CI
Jul. 01 Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) added to Russell Small Cap Completeness Index CI

Evolution of the average Target Price on Dianthus Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a0b7d189b.SK2Ih48xzNHmeUlteSnFvfQKtxemQcBfMNIMucAVkBI.Kf7Ft_1couanHR4KEnugiINAwlTEGK8UQuY4yZkswGQM7unXzgeTpqoePg~cc62e5840483410916e4dd188542f6ad

Analyst Recommendations on Dianthus Therapeutics, Inc.

Cantor Fitzgerald Initiates Dianthus Therapeutics at Overweight MT
HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target MT
Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating MT
Wedbush Raises Dianthus Therapeutics' PT to $33 From $24, Says Q4 2023 Results As-Expected, Keeps Outperform Rating MT
Stifel Initiates Dianthus Therapeutics With Buy Rating, $44 Price Target MT
Wedbush Lifts Dianthus Therapeutics' PT to $24 From $23, Updates Estimates Following Private Placement; Keeps Outperform Rating MT
Jefferies Initiates Dianthus Therapeutics at Buy With $22 Price Target MT
Wedbush Starts Dianthus Therapeutics With Outperform Rating, $23 Price Target; Sees DNTH103 as Promising Candidate MT
Raymond James Starts Dianthus Therapeutics at Outperform, $24 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
28.23 USD
Average target price
48.75 USD
Spread / Average Target
+72.69%
High Price Target
84 USD
Spread / Highest target
+197.56%
Low Price Target
38 USD
Spread / Lowest Target
+34.61%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Dianthus Therapeutics, Inc.

HC Wainwright
Wedbush
Stifel Nicolaus
Jefferies & Co.
Raymond James

Ratings for Dianthus Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. DNTH Stock
  4. Consensus Dianthus Therapeutics, Inc.